Form 4: Evolent Health CEO Blackley's Equity Transactions

Evolent Health CEO Seth Blackley reported recent acquisitions of common stock from PSU settlements and new PSU grants, alongside tax-related share disposals.

Summary

• CEO Seth Blackley acquired 58,921 shares of Class A Common Stock on March 2, 2026, from the settlement of performance-based share units (PSUs) awarded on March 1, 2024.
• The acquisition followed the Compensation Committee's certification of specified performance metrics, with the underlying PSU award vesting on December 31, 2025.
• Blackley disposed of a total of 51,326 shares of Class A Common Stock across three transactions (March 1, 2, and 3, 2026) to satisfy tax withholding obligations related to the vesting of restricted stock units and settlement of performance-based share units.
• On March 2, 2026, Blackley was granted 1,425,310 new performance-based share units (PSUs) under the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan.
• These new PSUs are subject to stock price performance conditions from March 1, 2027, to February 28, 2029, and service-based conditions, with potential earning ranging from 0% to 250% of the target level.
• Following these transactions, Blackley directly beneficially owns 836,962 shares of Class A Common Stock and 1,425,310 performance-based share units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects the successful vesting of prior performance-based awards and the grant of new, forward-looking performance incentives, aligning management with shareholder interests.

Positives

• Acquisition of 58,921 Class A Common Stock shares from the settlement of performance-based share units (PSUs) indicates successful achievement of prior performance metrics.
• Grant of 1,425,310 new performance-based share units (PSUs) aligns management incentives with future stock price performance, demonstrating confidence in long-term growth.

Negatives

• Disposal of 51,326 shares of Class A Common Stock for tax withholding purposes reduces direct beneficial ownership, though this is a standard practice for equity compensation.

Future Outlook

The grant of new performance-based share units (PSUs) to CEO Seth Blackley, with earning potential tied to stock price performance from March 1, 2027, to February 28, 2029, indicates a forward-looking incentive structure designed to align executive compensation with long-term shareholder value creation. The actual number of shares earned from these PSUs can range from 0% to 250% of the target level, contingent on achieving specified stock price and service-based conditions.

Industry Context

StockSavvy.ai notes that the use of performance-based share units (PSUs) and restricted stock units (RSUs) for executive compensation is a common practice in the healthcare technology and services industry. This approach aims to align the interests of executives with those of shareholders by tying a significant portion of compensation to company performance and stock appreciation. Competitors like Teladoc Health (TDOC) or Veeva Systems (VEEV) also frequently utilize similar equity compensation structures to incentivize leadership and retain talent in a competitive market.

Comparison to Industry Standards

• The structure of performance-based share units (PSUs) with a target level and a potential range of 0% to 250% based on performance metrics is consistent with best practices in executive compensation across various industries, including healthcare technology. This allows for significant upside for strong performance while mitigating risk for shareholders in case of underperformance.
• The practice of withholding shares to cover tax obligations upon vesting or settlement of equity awards is a standard and expected procedure for executive compensation, aligning with practices observed at companies like UnitedHealth Group (UNH) or Cigna (CI) for their executive equity plans.

Stakeholder Impact

• Shareholders: The grant of performance-based share units (PSUs) aligns the CEO's incentives directly with future stock price performance, potentially benefiting shareholders if performance targets are met. The successful vesting of previous PSUs indicates past performance achievements.
• Employees: No direct impact mentioned, but a well-incentivized CEO can contribute to overall company success, which indirectly benefits employees.

Next Steps

• Achievement of stock price performance conditions for the newly granted PSUs between March 1, 2027, and February 28, 2029.
• Satisfaction of service-based conditions for the newly granted PSUs.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of performance-based awards and the grant of new long-term incentives. While the successful vesting of prior PSUs is a positive indicator of past performance, and new PSU grants align management with future shareholder value, these are expected events and do not fundamentally alter the investment thesis for Evolent Health. The transactions do not suggest a significant change in the company's operational or financial outlook, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Evolent Health, EVH, Seth Blackley, Form 4, Insider Trading, Stock Transactions, Performance Share Units, Restricted Stock Units, Equity Compensation, CEO Stock